CXCR2 and neoplasm: Further studies showed that the inhibition of CXCR2 (a major CXCL‐1 receptor that is expressed by granulocytes), combined with the inhibition of CSF1R reduced both TAMs and PMN‐MDSCs in tumours, which significantly inhibited tumour growth.76 Moreover, such inhibition further enhanced the tumour inhibition ability of PD‐1 antibody.